The latest update is out from Prelude Therapeutics ( (PRLD) ).
Prelude Therapeutics has announced its presentation of clinical data on PRT3789, a groundbreaking treatment for cancers with SMARCA4 mutations, at the ESMO Congress 2024. This novel SMARCA2 degrader has shown promise in Phase 1 trials, demonstrating safety and potential efficacy, with Phase 2 dose recommendations expected by year-end. Prelude is also hosting an investor webcast to discuss these advancements, indicating a significant step forward in precision oncology.
See more data about PRLD stock on TipRanks’ Stock Analysis page.